Data to Be Presented At ESMO 2008 Highlight Pfizer Commitment to Cancer Care and Research
September 8th, 2008
Pfizer announced today that important study results involving the company‘s leading anticancer agent, SUTENT®(sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12-16 September 2008.
Researchers will present results of several analyses evaluating the cost effectiveness of SUTENT® as first-line therapy in patients with metastatic renal cell carcinoma (mRCC), as well as updated data from a pivotal Phase III trial in mRCC. In addition, researchers will present updated results for CP-751,871, a novel anti-IGF-1R antibody, and the first in its class to initiate Phase III trials in patients with non-small cell lung cancer (NSCLC).